Type I IFN Signaling on Both B and CD4 T Cells Is Required for Protective Antibody Response to Adenovirus
-
- Jiangao Zhu
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center , Durham, NC 27710
-
- Xiaopei Huang
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center , Durham, NC 27710
-
- Yiping Yang
- Department of Medicine, Division of Medical Oncology, Duke University Medical Center , Durham, NC 27710
書誌事項
- 公開日
- 2007-03
- 権利情報
-
- https://academic.oup.com/pages/standard-publication-reuse-rights
- DOI
-
- 10.4049/jimmunol.178.6.3505
- 公開者
- Oxford University Press (OUP)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Recombinant adenoviruses have been used as vehicles for gene therapy as well as vaccination against infectious diseases and cancer. Efficient activation of host B cell response to adenoviral vectors that leads to the generation of protective, neutralizing Ab, represents a major barrier for gene therapy, but an attractive feature for vaccine development. What regulate(s) potent B cell response to adenoviral vectors remains incompletely defined. In this study, we showed that type I IFNs induced upon adenoviral infection are critical for multiple stages of adaptive B cell response to adenovirus including early B cell activation, germinal center formation, Ig isotype switching as well as plasma cell differentiation. We further demonstrated that although type I IFN signaling on dendritic cells was important for the production of virus-specific IgM, the generation of protective neutralizing Ab critically depended on type I IFN signaling on both CD4 T and B cells. The results may suggest potential strategies for improving adenovirus-mediated gene therapy in vivo and/or the design of effective vaccines for cancer and infectious diseases.</jats:p>
収録刊行物
-
- The Journal of Immunology
-
The Journal of Immunology 178 (6), 3505-3510, 2007-03
Oxford University Press (OUP)